{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.10","value":"73.4"},{"groupId":"OG001","spread":"18.66","value":"46.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Minimum observed serum concentration (trough)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by in situ hybridization (ISH) and HER2 overexpression by immunohistochemistry (IHC) which includes IHC 2+ or 3+","id":"OG000","title":"Cohort I"},{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by ISH and HER2 IHC 0 or 1+.","id":"OG001","title":"Cohort II"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All subjects who received any amount of zanidatamab and have at least 1 post-baseline pharmacokinetic (PK) assessment were included in this outcome.","reportingStatus":"POSTED","timeFrame":"Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose","title":"Trough Concentration of ZW25","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter"}